Illinois enacted the Wellness and Oversight for Psychological Resources Act, establishing standards for the use of AI technology in the provision of therapy and psychotherapy services. The Act aims to protect consumers by...more
Jeremy Sherer and Amy Joseph discuss: The state law doctrine and the policy behind it How it may impact your business structure
Amy: Jeremy, a lot of our clients that come to us are founders who are new to healthcare. Can...more
The Calendar Year 2026 Medicare Physician Fee Schedule (PFS) proposed rule (see Orrick’s analysis of the proposed rule here) contains important signals for the future of remote patient monitoring (RPM) and remote therapeutic...more
8/4/2025
/ Centers for Medicare & Medicaid Services (CMS) ,
Healthcare ,
Healthcare Fraud ,
Medicare ,
OIG ,
Physician Fee Schedule ,
Proposed Rules ,
Regulatory Oversight ,
Regulatory Requirements ,
Reimbursements ,
Telehealth
The Centers for Medicare & Medicaid Services (CMS) published proposed versions of the Calendar Year 2026 (CY 2026) Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System (OPPS) rules on July 16, 2025,...more
This year, U.S. VC funding into the life sciences sector has cooled: Q1 softness was followed by a decade low in VC transactions in Q2. Despite the moderation in dealmaking volume, investors continued to deploy sizable...more
Amy Joseph shares advice on: How to navigate fraud & abuse laws Key questions to help your company structure a compensation arrangement...more
Q1 2025 marked another strong quarter for life sciences VC financing, but the industry faces unique headwinds amid ongoing shake-ups in regulatory leadership and US trade relationships. Key takeaways for Q1 2025 include: •...more
Q4 2024 marked the conclusion of a turnaround year for life sciences venture investment. After two consecutive years of declining activity and macroeconomic uncertainty, the dust has settled, and investment is back on the...more
The FDA has shared its first draft guidance on how sponsors should assess the credibility of artificial intelligence (AI) models to support FDA decisions regarding drug safety, effectiveness or quality. The agency noted an...more
The FDA has shared draft guidance on the design and development of AI-enabled medical devices and marketing submissions for those devices. The Importance of Engaging Early Sponsors of AI-enabled devices should engage with the...more
Republished with Permission
In this Law360 article, partners Thora Johnson, Georgia Ravitz and Amy Joseph explore the notable trends to watch in health tech regulation this coming year. The article observes that the...more
The Drug Enforcement Administration (DEA) has issued the “Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications” (Third Extension), which extends the flexibilities...more
Since the previous quarter’s Life Sciences Snapshot, robust dealmaking activity in Q3 has launched YTD life sciences VC deal activity to near parity with 2023 figures, firmly positioning 2024 as the year to break the two-year...more
For some companies that make and distribute medical devices and drugs, and for group purchasing organizations (GPOs), reporting financial information to the U.S. government has become a regular part of doing business. The...more
The health care industry has utilized artificial intelligence for decades, but the recent expansion of AI’s capabilities into generative AI models is raising questions about how and to what extent to regulate the technology....more
The Texas Attorney General is once again signaling the office’s intent to enforce the state’s privacy and consumer protection laws. According to a June 2024 press release, Texas Attorney General Ken Paxton “launched a major...more
Generative AI is converging with every sector – and health care is no exception. With it, companies should keep up with the array of laws and regulations – existing and envisioned – that govern its use. Read on for highlights...more
Federal agencies and lawmakers in several states are attempting to rewrite the rulebook for private investment in health care in the U.S. California and other states are considering new regulations reinforcing state...more